RAVIMIAMET

Ravimiohutus

Maia Uusküla

02.06.2015, Tartu

PSUR
perioodiline ohutusaruanne

Mõisted

- PSUR – Periodic Safety Update Report (perioodiline ohutusaruanne)
- PBRER – Periodic benefit-risk evaluation report = PSUR

  PSUR – EU määrustes, juhendites

  PBRER – ICH juhendites
- PSUSA – protseduur – PSURi ühtne hindamise protseduur
- AR – hinnanguaruanne (mis võib olla mitme MLH mitme PSURi kohta = PSUSA)

DSUR

- **DSUR - Development Safety Update Report – aastane ohutusaruanne kliinilise uuringu ravimi kohta**

Tuleb esitada:

clinical.trials@ravimiamet.ee

mitte pharmacovig@ravimiamet.ee

mitte documentation@ravimiamet.ee

DSUR

Rohkem infot

- http://www.hma.eu/ctfg.html

- http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2011_12_22_Q___A_DSUR.pdf

PSUR

EURD nimekiri - EURD list

Leitav EMA veebis (info ja tabel)

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/09/news_detail_001616.jsp&mid=WC0b01ac058004d5c1

HMA veebis PSUR WS nimekiri

http://www.hma.eu/348.html

PSUR WS või riiklik hindamine jätkub kuni nimekirjas olevate toimeainete DLP on möödas.

Riikliku MLga ravimi puhul, mille toimeaine(d) ei ole EURD nimekirjas, toimub PSUR hindamine riiklikul tasandil (ajakava vastavalt määrusele)

PSUR esitamine

- praegu veel Ravimiametile
CESP, documentation@ravimiamet.ee
või CD/DVD9

JA
EMA (PSUR repository),

peagi ainult EMA PSUR repository

mitte pharmacovig@ravimiamet.ee

HMA WS list

2015_01_PSUR_WS.pdf - Adobe Reader

File Edit View Window Help

1 / 27 94,3% Tools Sign Comment

List of substances under PSUR Work Sharing scheme and other substances contained in Nationally Authorised Products with DLP synchronised
Status January 2015 - In Red font: changes made since last publication in November2014

Active substance name (INN)	Innovator brand name (for fixed combination products only)	EU HBD	DLP (year and month)	MAH of the reference product	Comments	Allocated P-RMS / Procedure number	Note on PSUR cycle	Next DLP	Submission of PSURs by (DLP + 90 days by default)	Are PSURs required for products referred to in Articles 10(1), 10a, 14 and 16a of Directive 2001/83/EC as amended?	Substances under PSUR Work Sharing scheme or Others (contained in Nationally Authorised Products including MRP/DCP)
~~human coagulation factor VII~~		~~01/11/1975~~	~~201310~~	~~Baxter~~	The PSUR WS assessment for the corresponding DLP has been finalised, and that the next PSUR shall be submitted according to the EURD list.	~~AT/H/PSUR/0042/001~~			~~201401~~	~~No, except if required nationally by a competent authority~~	~~Work Sharing~~
atorvastatin (paediatric indication)		07/11/1996	31/10/2013	Pfizer	The PSURs corresponding to DLPs 31/10/2013 and 31/10/2014 should be submitted in accordance with the List of substances under PSUR Work Sharing scheme and other substances contained in Nationally Authorised Products with DLP synchronised. The EURD list should be consulted for the submission of PSURs following the DLP 31/10/2014.	DE/H/PSUR/0048/001	yearly PSURs	31/10/2014	29/01/2014	No, except if required nationally by a competent authority	Work Sharing
~~mepivacaine~~		~~19560401~~	~~201303~~	~~AstraZeneca~~	The PSUR WS assessment for the corresponding DLP has been finalised, and that the next PSUR shall be submitted according to the EURD list	~~DK/H/PSUR/0057/001~~			~~201306~~	~~No, except if required nationally by a competent authority~~	~~Work Sharing~~
~~paricalcitol~~		~~19980417~~	~~201308~~	~~Abbott~~	The PSUR WS assessment for the corresponding DLP has been finalised, and that the next PSUR shall be submitted according to the EURD list	~~ES/H/PSUR/0016/003~~			~~201311~~	~~No, except if required nationally by a competent authority~~	~~Work Sharing~~
ethinylestradiol, gestodene (transdermal application)	Bayer Pharma AG	11/02/2014	11/08/2014		The next PSUR shall be submitted according to the EURD list	FR/H/PSUR/0073/001			20/10/2014	No, except if required nationally by a competent authority	Work Sharing

EURD list

Active substances and combinations of active substances	European Union reference date (EURD) Not Available* = EURD not provided during the consultation phases	PSUR Sub-mission Frequency	DLP	Submission date (According to the timelines defined in GVP Module VII, Section A)	Next DLP (For active substances or combination of active substances with a PSUR frequency of less than one year)	Next Submission date (According to the timelines defined in GVP Module VII, Section A - For active substances or combination of active substances with a PSUR frequency of less than one year)
testosterone undecylate (injection)	25.11.2003	1 year	24.11.2014	2.02.2015	31.12.2015	30.03.2016

EURD list

Are PSURs required for products referred to in Articles 10(1), 10a, 14, 16a of Directive 2001/83/EC as amended? Yes/No	Publication Date (in accordance with Article 107c(7) of Directive 2001/83/EC as amended)	Notes	Procedure number of the PSUR single assessment (DLP)	Procedure number of the PSUR single assessment procedure (Next DLP)
Yes	28.05.2014	PRAC representative name was corrected on 16/01/2015 Lead MS was appointed on 22/12/2014 Conditions to the marketing authorisation following referral Art 31	PSUSA/00010161/201411	PSUSA/00010161/201512

EURD list

PRAC representative of the PSUR single assessment procedure	(Lead) Member State of the PSUR single assessment procedure	Centrally authorised product(s) (CAP)	Nationally authorised product(s) (NAP)
Maia Uusküla	Estonia		NAP

PSUSA

Protseduuri koordineerib EMA

Hindamist juhib:

- **PSUSA, mis sisaldab tsentraalset ML: PRAC liige**
- **PSUSA, mis ei sisalda ühtegi tsentraalset ML: CMD(h) määrab hindava liikmesriigi („lead MS“) 6 kuud enne starti**

- **Protseduuri lõpus PRAC recommendation**

- **2 kuud enne starti saadab EMA MLH-le väljavõtte Art.57 andmebaasist koos PSUSA numbriga (advice note)**

PSUSA ajakava

DLP	24 Nov 2014
Submission date by MAH (to EMA)	2 Feb 2015
Start of procedure (at MS level)	12 March 2015
Preliminary assessment by:	11 May 2015
MAH comments on the preliminary assessment by:	10 June 2015
Updated AR by:	25 June 2015
PRAC recommendation:	9 July 2015

MS saadab AR'i EMA'le
EMA edastab MLH'le.
Kommentaarid MLH'lt – EMAl'e

PSUSA tasu

REGULATION (EU) No 658/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 May 2014

EMA esitab MLH'(te)le arve

The fee for the assessment of periodic safety update reports shall be EUR 19 500 per procedure

In application of Article 4(5), small and medium-sized enterprises shall pay 60 % of the applicable amount.

DHPC/aRMM

ohutusalane teabekiri
täiendavad riskivähendamise meetmed

DHPC/aRMM

pharmacovig@ravimiamet.ee

Juhendid on veebis:

Ettevõtjale – inimestel kasutatavad ravimid – ravimiohutus

- **Ravimiameti juhend riskiminimeerimise lisameetmete materjalide esitamiseks**
- **Ravimiameti juhend ohutusalase teabekirja kooskõlastamiseks**

DHPC/aRMM

pharmacovig@ravimiamet.ee

Selge kirja päis: Ravimi nimetus, aRMM / DHPC, esmane või korduv

Kirjas tuleb selgitada, mis on materjalide saatmise põhjuseks (müügiloa tingimus - Lisa II D, riskijuhtimiskavas kinnitatud nõuded)

Kui tegu on korduvate materjalidega, tuleb selgitada, millal eelmine kord materjalid on kinnitatud ja mis on peamised muudatused. Muudatused tuleb teha nähtavalt (träkiga).

Versiooninumber

DHPC/aRMM

Kommunikatsiooniplaan (kellele suunatud, kuidas levitatakse ja millal), korduvate materjalide puhul selgitus, kuidas tagatakse eelneva versiooni tagasikorjamine/hävitamine.

Eesti keelt valdav kontaktisik (nõue tuleneb Sotsiaalministri määrusest nr 26 § 4 lõige 4).

MLH eesti keelt kõnelev kontakt ka arsti materjalil /DHPC kirjal

DHPC/aRMM

MLH peab kommunikatsiooniplaanis toodud sihtgrupi kohta pidama arvestust (kellele konkreetselt on materjalid edastatud ja millal).

RavS § 783 lg 2 punkt 11 - ravimiohutuse heade tavade (GVP) moodul XVI punkt XVI.B.6:

The marketing authorisation holder should ensure appropriate version control of the risk minimisation tools in order to ensure that all healthcare professionals and patients receive up-to-date risk minimisation tools in a timely manner and that the tools in circulation are consistent with the approved product information. To this purpose the market authorisation holders are encouraged to keep track of the receipt of any risk minimisation tools. These records may be subject to audit and inspection.

DHPC

Kirjad avaldame veebis

Andke teada/lisage

pharmacovig@ravimiamet.ee

kirjasaajate listi

Kirjanduse monitoorimine

Kirjanduse monitoorimine

- Eesti Arst, Perearst
- Elektroonsed (med24, MU.ee) - võib vaadata, ei ole kohustatud

Kirjanduse monitoorimine

EMA monitoorib teatud toimeaineid (lisandub juurde) ja teatud saite.

As of the 1st July 2015, the service will cover the top 50 active chemical substance groups. The medical literature monitoring service is expected to reach full operational levels by September 2015.

Home - human regulatory - pharmacovigilance – medical literature monitoring

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000633.jsp&mid=WC0b01ac05808ce84c

Kirjanduse monitoorimine



WC500186735 [Read-Only] - Microsoft Excel

ID	Substance Group	Substances
1	PARACETAMOL	ACETYLCYSTEINE, PARACETAMOL
1	PARACETAMOL	ACETYLSALICYLIC ACID, ANHYDROUS CAFFEINE, PARACETAMOL DC
1	PARACETAMOL	ASCORBIC ACID, CHLORPHENAMINE, PARACETAMOL
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, ACETYLSALICYLIC ACID
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, ANHYDROUS CAFFEINE
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, CAFFEINE
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, PHENYLEPHRINE
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, POTASSIUM HYDROGEN CARBONATE, SODIUM HYDROGEN CARBONATE, SODIUM CARBONATE ANHYDROUS,
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, PROPYPHENAZONE
1	PARACETAMOL	ASCORBIC ACID, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE
1	PARACETAMOL	BROMPHENIRAMINE MALEATE, ASCORBIC ACID, PARACETAMOL, CAFFEINE
1	PARACETAMOL	BROMPHENIRAMINE MALEATE, PARACETAMOL, CAFFEINE
1	PARACETAMOL	BUCLIZINE HYDROCHLORIDE, CODEINE PHOSPHATE, PARACETAMOL DC
1	PARACETAMOL	BUCLIZINE HYDROCHLORIDE, DOCUSATE SODIUM, PARACETAMOL, CODEINE PHOSPHATE
1	PARACETAMOL	CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE PHEUR, PARACETAMOL PH. EUR.
1	PARACETAMOL	CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE, PARACETAMOL PH. EUR.
1	PARACETAMOL	CAFFEINE, PARACETAMOL PH. EUR.
1	PARACETAMOL	CARBASALATE CALCIUM, PARACETAMOL, CAFFEINE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, ASCORBIC ACID, DIMETOFRINE, ISOPROPAMIDE IODIDE, PARACETAMOL, ANHYDROUS CAFFEINE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, ASCORBIC ACID, ISOPROPAMIDE IODIDE, PARACETAMOL, CAFFEINE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, ASCORBIC ACID, ISOPROPAMIDE IODIDE, PARACETAMOL, DIMETOFRINE HYDROCHLORIDE, ANHYDROUS CAFFEI
1	PARACETAMOL	CHLORPHENAMINE MALEATE, ASCORBIC ACID, PARACETAMOL
1	PARACETAMOL	CHLORPHENAMINE MALEATE, ASCORBIC ACID, PARACETAMOL, CAFFEINE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, ASCORBIC ACID, PARACETAMOL, CAFFEINE CITRATE, DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL
1	PARACETAMOL	CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL
1	PARACETAMOL	CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL
1	PARACETAMOL	CHLORPHENAMINE MALEATE, DIPROPHYLLINE, GUAIFENESIN, PARACETAMOL
1	PARACETAMOL	CHLORPHENAMINE MALEATE, ISOPROPAMIDE IODIDE, PARACETAMOL, CAFFEINE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, PARACETAMOL
1	PARACETAMOL	CHLORPHENAMINE MALEATE, PARACETAMOL, ACETYLSALICYLIC ACID, ANHYDROUS CAFFEINE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, PARACETAMOL, CAFFEINE
1	PARACETAMOL	CHLORPHENAMINE MALEATE, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE

Kirjanduse monitoorimine



Description of the Journal/Reference databases

- EMBASE, a large, comprehensive and widely used, daily updated and indexed biomedical reference database covering literature from EEA and non-EEA countries.
  - The journal titles covered in Embase can be accessed here.
  - Information on the conference coverage can be obtained here.
- EBSCO covers a wide variety of resources, whereby the main focus will be put on the use of:
  - Medline Plus: further information on full text articles can be obtained here and the subject title list can be accessed here
  - International Pharmaceutical Abstracts (IPA) covering a broad spectrum of drug therapy and pharmaceutical information from over 800 pharmaceutical, medical, and health-related journals.
  - The Allied and the Complementary Medicine Database (AMED) covering alternative treatments based on bibliographic records for relevant articles from nearly 600 journals. The scope of coverage within this resource is mainly European.

Kirjanduse monitoorimine

Eesti Arst on EMA monitooritavas ajakirjade nimekirjas

NB! EMA monitoorib ainult teatud toimeaineid!

Teiste toimeainete osas peab ikka Eesti Arsti skriinima.

Kirjanduse monitoorimine



Ravimiohutuse inspektsioonid

PhV inspektsioonid

Ravimiohutuse inspektor - Ireen Reier

Inspektsioonist võtab osa lisaks üks Ravimiameti töötaja (kas GCP inspektor või Ohutusbüroo juhataja)

Juhindume Ravimiseadusest, EL direktiivist, GVPst

Inspekteerime Eesti MLH ja filiaale, sh veterinaarravimite MLH

PhV inspektsioonid

Teavitame inspekteeritavat MLH'd/MLH filiaali minimaalselt 1 kuu enne plaanitavat rutiinset inspektsiooni, küsime ette dokumente (meili teel).

MLH'lt ootame ruumi olemasolu, kus inspektorid saavad olla (vajadusel) omaette

Ligipääs andmebaasidele (st arvuti, internet)

Koopiate tegemise võimalus

Dokumente küsime lisaks kohapeal

Vestlused MLH töötajatega

PhV inspektsioonid

Inspektsiooni kokkuvõtval koosolekul antakse teada üldsõnaliselt puudused (neid klassifitseerimata)

1 kuu jooksul pärast inspektsiooni saadetakse MLH'le inspektsiooniakt (vajadusel puuduste osa ka inglise keeles)

RAVIMIAMET

Tänan kuulamast!

Küsimused:

Maia.Uuskula@ravimiamet.ee

pharmacovig@ravimiamet.ee